January 2026 in “Quality in Sport” This review highlights that isotretinoin effectively treats acne by addressing its pathogenic mechanisms, although managing its teratogenic risk and side effects through structured monitoring is crucial for safe use.
98 citations
,
May 2010 in “British Journal of Dermatology” This document discusses the British Association of Dermatologists' current perspective on isotretinoin, focusing on its known side effects, prescribing requirements, teratogenic risks, and the contentious link to mood changes, reporting no new research findings.
4 citations
,
September 2014 in “Elsevier eBooks” This review discusses the safety of dermatological medications used during pregnancy, highlighting that retinoids have strong teratogenic risks and should be used with caution; it reports no new clinical results.
19 citations
,
March 2021 in “Experimental and Therapeutic Medicine” This review examines recent literature on isotretinoin's teratogenic effects in both fertile females and males, analyzing its role in causing congenital malformations but provides no new clinical results.
87 citations
,
July 2012 in “Expert Review of Clinical Immunology” This review outlines pregnancy risks in systemic lupus erythematosus and emphasizes that active lupus nephritis at conception increases the risk of flares and poor obstetric outcomes; it reports no new clinical findings.